Celgene Corporation to Acquire Juno Therapeutics, Inc.
- Acquisition Will Add Novel Scientific Platform and Manufacturing Expertise to Celgene?s Research and Operational Capabilities
- JCAR017 is Expected to be a Significant Growth Driver Beyond 2020 with Potential Global Peak Sales of Approximately $3B
- Reaffirming 2020 Financial Targets of $19B-$20B in Total Net Product Sales and Adjusted EPS Greater Than $12.50
- Leverage a novel scientific platform and scalable manufacturing capabilities to position Celgene at the forefront of future advances in the science of cellular immunotherapy
- Accelerate Juno?s pipeline development to capture the full potential of cellular immunotherapy
- JCAR017, a pivotal stage asset, with an emerging favorable profile in DLBCL, is expected to add approximately $3 billion in peak sales and significantly strengthen Celgene?s lymphoma portfolio
- JCARH125 will enhance Celgene?s campaign against BCMA (B-cell maturation antigen), a key target in multiple myeloma
- Additional cellular therapy assets in proof-of-concept trials for hematologic malignancies and solid tumors will add to Celgene?s existing pipeline
- Accelerate revenue diversification with meaningful growth drivers beyond 2020
- Capture 100% of the global economics on all Juno?s cellular immunotherapy assets
View source version on businesswire.com: http://www.businesswire.com/news/home/20180122005858/en/
For Celgene: Investors: 908-673-9628 investors@celgene.com or Media: 908-673-2275 media@celgene.com Source: Celgene Corporation News Provided by Acquire Media